Skip to main content
Article thumbnail
Location of Repository

Clinical Effects of Calcium Channel Blocker and Angiotensin Converting Enzyme Inhibitor on Endothelial Function and Arterial Stiffness in Patients with Angina Pectoris

By Kye Hun Kim, Myung Ho Jeong, Sook Hee Cho, Jae Youn Moon, Young Joon Hong, Hyung Wook Park, Ju Han Kim, Youngkeun Ahn, Jeong Gwan Cho, Jong Chun Park and Jung Chaee Kang

Abstract

To evaluate the effects of calcium channel blocker (CCB) and angiotensin converting enzyme inhibitor (ACEI) on endothelial function and arterial stiffness in stable angina pectoris (SAP), 87 patients with SAP (57.6±10.0 yr, 52 males) were divided into two groups; CCB group (group I: n=44, 57.9±9.7 yr, 23 males) vs. CCB plus ACEI group (group II: n=43, 57.2±10.5 yr, 29 males). Flow mediated vasodilation (FMD) of the brachial artery, pulse wave velocity (PWV), urinary albumin excretion (UAE), and high sensitivity C-reactive protein (hsCRP) were compared. FMD, PWV, UAE, and hsCRP were not different between the groups at baseline. After 6 months of treatment, FMD were significantly improved in group II (7.5±3.7 to 8.8±2.7%, p<0.001), but not in group I (7.9±2.7 to 8.2±2.8%, p=0.535). Brachial-ankle PWV were significantly improved in both groups (1,621.3±279.4 to 1,512.1±225.0 cm/sec in group I, p<0.001, 1,586.8±278.5 to 1,434.5±200.5 cm/sec in group II, p<0.001). However, heart-femoral PWV were significantly improved (1,025.7±145.1 to 946.2±112.2 cm/sec, p<0.001) and UAE were significantly decreased (20.19±29.92 to 13.03±16.42 mg/g Cr, p=0.019) in group II only. In conclusion, combination therapy with CCB and ACEI improves endothelial function, arterial stiffness, and UAE than CCB mono-therapy more effectively in patients with SAP

Topics: Original Article
Publisher: The Korean Academy of Medical Sciences
OAI identifier: oai:pubmedcentral.nih.gov:2672120
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2002). American College of Cardiology;
    2. (1996). Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation
    3. (2003). Antihypertensive drugs and arterial stiffness. Expert Rev Cardiovasc Ther
    4. (2005). Aortic pressure augmentation predicts adverse cardiovascular events in patients with established coronary artery disease. Hypertension
    5. (2004). Arterial stiffness, wave reflections, and the risk of coronary artery disease. Circulation
    6. (2001). Arterial stiffness: clinical relevance, measurement, and treatment. Rev Cardiovasc Med
    7. (2004). Arterial stiffness: pathophysiology and clinical impact. Clin Exp Hypertens
    8. (1999). Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation
    9. (2001). Association between arterial stiffness and atherosclerosis: the Rotterdam Study. Stroke
    10. (2005). Association between serum C-reactive protein levels and pulse wave velocity: a population-based cross-sectional study in a general population. Atherosclerosis
    11. (1999). C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation
    12. (1991). Cardiovascular disease risk profiles.
    13. (1997). Cell dysfunction in atherosclerosis and the ischemic manifestations of coronary artery Endothelial Function and Arterial Stiffness in Angina Pectoris 229disease.
    14. (2000). Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study).
    15. (2002). Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.
    16. (2006). Diverse associations of microalbuminuria with C-reactive protein, interleukin 18 and soluble CD 40 ligand in male essential hypertensive subjects.
    17. (2004). Effect of different antihypertensive drug classes on central aortic pressure.
    18. (2000). Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation
    19. (2004). Emerging, noninvasive surrogate markers of atherosclerosis. Curr Atheroscler Rep
    20. (2003). Endothelial dysfunction: a marker of atherosclerotic risk. Atherioscler Thromb Vasc Biol
    21. (1997). Endothelial function as a determinants of vascular function and structure: a new therapeutic target.
    22. (2005). Endothelial vasomotor dysfunction in the brachial artery is associated with late in-stent coronary restenosis.
    23. (2004). High brachial-ankle pulse wave velocity is an independent predictor of the presence of coronary artery disease in men. Hypertens Res
    24. (2005). Impaired flow-mediated dilation and risk of restenosis in patients undergoing coronary stent implantation. Circulation
    25. (2002). International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial dependent flow mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force.
    26. (2004). Interrelationship between noninvasive measurements of atherosclerosis: flow-mediated dilation of brachial artery, carotid intima-media thickness and pulse wave velocity. Atherosclerosis
    27. (2007). Measurement of the brachial-ankle pulse wave velocity and flow-mediated
    28. (1999). Microalbuminuria as a predictive factor for cardiovascular events.
    29. (2003). Relation between conduit vessel stiffness (assessed by tonometry) and endothelial function (assessed by flow-mediated dilatation) in patients with and without coronary heart disease.
    30. (2006). Relation of microalbuminuria and coronary artery disease in patients with and without diabetes mellitus.
    31. (2007). Renal and vascular protective effects of cilnidipine in patients with essential hypertension.
    32. (2003). Rosano GM. In patients with coronary artery disease endothelial function is associated with plasma levels of C-reactive protein and is improved by optimal medical therapy. Ital Heart J
    33. (2004). Surrogate markers for cardiovascular disease: functional markers. Circulation
    34. (1993). The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature
    35. (2002). Treatment of microalbuminuria in patients with type 2 diabetes mellitus. Treat Endocrinol

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.